Ivey Business School (Canada)
-
Filter Innovations Inc.
Elizabeth M.A. Grasby; Jessica JohnCase IVEY-9B10B008-EAccounting and Control, EntrepreneurshipThe president of a small water filtration company is considering expanding his operations to include membrane biological reactors (MBRs). The topic of future-oriented decision-making using the differential cash flow is introduced. Students are asked to (1) qualitatively evaluate the filtration industry and decide whether this is the right time for the company to expand to MBRs; (2) perform a business size-up of the company and its competitors and...Starting at €8.20
-
Arts and Communications Counselors Inc.
Elizabeth M.A. Grasby; Jessica JohnCase IVEY-9B10N005-EAccounting and Control, FinanceThe president of a small Toronto, Ontario consulting firm specializing in sponsorship and experimental marketing looks at adding a public relations division to the firm. Students are required to analyze the external environment, identify corporate strengths and weaknesses, identify qualitative pros and cons, prepare projected statements, look at the timeliness of the option, and evaluate the business plan before arriving at a final decision.Starting at €8.20
-
The Heat is ON
Mark Zbaracki; Maziar RazCase IVEY-9B14M097-EEntrepreneurship, StrategyIn January 2014, the chief executive officer of AutoTherm, a small smart-thermostat design company located in Toronto, Canada, was considering the company’s future in light of the uncertainties and fast changing dynamics of the industry. As an incumbent and small engineering firm, AutoTherm’s plans to sell its first product, B133, through partnership with a large electronics company had not been quite successful. Given the dire state of the compa...Starting at €8.20
-
Hoffmann-La Roche: Pricing the Zelboraf Melanoma Treatment for Canada
Mark Zbaracki; Jedy WangCase IVEY-9B16M138-EStrategyThe Canadian brand manager of Zelboraf had to decide how to introduce and price Zelboraf in the Canadian market. Zelboraf was a breakthrough discovery in treatment for melanoma cancer patients. Hoffmann-La Roche (Roche) began developing Zelboraf in 2005. During the clinical trials, the drug yielded such positive results in targeting late-stage (metastatic) melanoma cancer that Roche ended clinical trials early in order to expedite FDA approval an...Starting at €8.20